Literature DB >> 22161225

Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Maria Koutsaki1, Apostolos Zaravinos, Demetrios A Spandidos.   

Abstract

Ovarian cancer (OC) is a heterogeneous disease, including a broad spectrum of histological subtypes and demonstrating diverse biological behavior. Epithelial-derived ovarian malignant tumours constitute the predominant and most lethal form of the disease. Age, genetic predisposition, gynecological and reproductive factors and environmental factors are the main risk factors that increase the risk for acquiring OC. Vaginal examination, ultrasonography and measurement of blood serum levels of tumour markers, especially CA125 constitute the first-line screening modalities for OC, whereas second-line testing involves more accurate imaging techniques such as color Doppler ultrasound of the lesion or/and a CT scan. Sex steroid hormone pathway genes, cell cycle genes, DNA repair genes, oncogenes and onco-suppressor genes have been associated with a genetic susceptibility to sporadic OC. In the present review we focus on the major oncogenes and onco-suppressor genes in the sporadic form of the disease. Each tumour subtype is associated with a unique molecular signature, as revealed by current genetic and biomarker profiling studies. Different OC pathways emerge early in the process of carcinogenesis, ultimately leading to clinically different tumour types. As mutations acquired early during tumourigenesis will be present in all later stages, large-scale gene expression profiling using DNA microarray analysis techniques can help to classify ovarian cancers into clinically relevant subtypes.

Entities:  

Mesh:

Year:  2011        PMID: 22161225     DOI: 10.1007/s12253-011-9482-8

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  158 in total

1.  PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma.

Authors:  R L Levine; C B Cargile; M S Blazes; B van Rees; R J Kurman; L H Ellenson
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

Review 2.  Involvement of the ras genes in female genital tract cancer.

Authors:  Ioannis N Mammas; Alexandros Zafiropoulos; Demetrios A Spandidos
Journal:  Int J Oncol       Date:  2005-05       Impact factor: 5.650

3.  The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.

Authors:  David Shahbazian; Philippe P Roux; Virginie Mieulet; Michael S Cohen; Brian Raught; Jack Taunton; John W B Hershey; John Blenis; Mario Pende; Nahum Sonenberg
Journal:  EMBO J       Date:  2006-06-08       Impact factor: 11.598

4.  An abundance of p53 null mutations in ovarian carcinoma.

Authors:  J S Skilling; A Sood; T Niemann; D J Lager; R E Buller
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

5.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

6.  Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Authors:  Daniel G Rosen; Lin Wang; J Neeley Atkinson; Yinhua Yu; Karen H Lu; Eleftherios P Diamandis; Ingegerd Hellstrom; Samuel C Mok; Jinsong Liu; Robert C Bast
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

7.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

8.  Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study.

Authors:  Ko-Hui Tung; Marc T Goodman; Anna H Wu; Katharine McDuffie; Lynne R Wilkens; Laurence N Kolonel; Abraham M Y Nomura; Keith Y Terada; Michael E Carney; Leslie H Sobin
Journal:  Am J Epidemiol       Date:  2003-10-01       Impact factor: 4.897

9.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

Review 10.  Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.

Authors:  Michèle Sabbah; Shahin Emami; Gérard Redeuilh; Sylvia Julien; Grégoire Prévost; Amazia Zimber; Radia Ouelaa; Marc Bracke; Olivier De Wever; Christian Gespach
Journal:  Drug Resist Updat       Date:  2008-08-20       Impact factor: 18.500

View more
  3 in total

Review 1.  Ovarian cancer biomarker discovery based on genomic approaches.

Authors:  Jung-Yun Lee; Hee Seung Kim; Dong Hoon Suh; Mi-Kyung Kim; Hyun Hoon Chung; Yong-Sang Song
Journal:  J Cancer Prev       Date:  2013-12

2.  Long noncoding RNA MAGI1-IT1 promoted invasion and metastasis of epithelial ovarian cancer via the miR-200a/ZEB axis.

Authors:  Hao Gao; Xiaofeng Li; Guangxi Zhan; Yong Zhu; Jing Yu; Jiapo Wang; Li Li; Weimin Wu; Na Liu; Xiaoqing Guo
Journal:  Cell Cycle       Date:  2019-06-03       Impact factor: 4.534

Review 3.  The miR-200 family in ovarian cancer.

Authors:  Maria Koutsaki; Massimo Libra; Demetrios A Spandidos; Apostolos Zaravinos
Journal:  Oncotarget       Date:  2017-06-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.